Eschalier Alain, Courteix Christine
INSERM, U766, Faculté de médecine, Université d'Auvergne, 63001 Clermont-Ferrand, France.
Rev Med Suisse. 2007 Jun 20;3(116):1581-4.
A balanced inhibition of both serotonin and norepinephrine reuptake is usually evoked to explain the analgesic action of tricyclic and SNRI antidepressants but other mechanisms able to modulate the chronic pain-induced neuroplasticity may occur. Fundamental and clinical experiments are necessary to confirm the traditional monoaminergic hypothesis, to improve the efficacy of SRI and to better define the criteria of choice of antidepressants. These could open on novel therapeutic approaches for the management of chronic neuropathic pains as, for example the medication combination.
通常认为,三环类和5-羟色胺-去甲肾上腺素再摄取抑制剂(SNRI)类抗抑郁药的镇痛作用是由5-羟色胺和去甲肾上腺素再摄取的平衡抑制引起的,但可能还存在其他能够调节慢性疼痛诱导的神经可塑性的机制。有必要进行基础和临床实验来证实传统的单胺能假说,提高5-羟色胺-去甲肾上腺素再摄取抑制剂(SRI)的疗效,并更好地确定抗抑郁药的选择标准。这些研究可能会为慢性神经性疼痛的治疗开辟新的途径,例如药物联合使用。